Novartis RNA pullback gives biotech stocks whiplash
This article was originally published in Scrip
Executive Summary
Novartis stopped short of saying it has given up on RNA therapeutics entirely, but the company's pullback from the sector hurt several public biotechnology firms whose stocks declined in the US based on statements from the Swiss drug maker.
You may also be interested in...
Dicerna, Flush With Cash, Is Back To The Drawing Board
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.